mlkrborn
12 years ago
Tegal Corporation to Acquire CollabRx, Inc.
Date : 07/02/2012 @ 7:01AM
Source : Business Wire
Stock : Tegal Corp. (MM) (TGAL)
Quote : 5.2 1.6 (44.44%) @ 1:00PM
Tegal Corporation to Acquire CollabRx, Inc.
Print
Alert
Tegal (NASDAQ:TGAL)
Intraday Stock Chart
Today : Monday 2 July 2012
Tegal Corporation (NASDAQ:TGAL) today announced that it has signed a definitive agreement to acquire CollabRx, Inc., a privately held technology company in the rapidly growing market of interpretive content and data analytics for genomics-based medicine.
CollabRx offers cloud-based expert systems that provide clinically relevant interpretive knowledge to institutions, physicians, researchers and patients for genomics-based medicine in cancer and other diseases to inform health care decision making. With access to approximately 50 clinical and scientific advisors at leading academic institutions and a suite of tools and processes that combine artificial intelligence-based analytics with proprietary interpretive content, the company is well positioned to participate in the $300 billion value-added “big data” opportunity in the US health care market (as reported by McKinsey Global Institute), over half of which specifically targets areas in cancer and cancer genomics.1
The Chief Executive Officers of the two constituent companies, Thomas Mika of Tegal and James Karis of CollabRx, plan to serve as co-CEOs of the combined, publicly traded company, with headquarters in San Francisco, CA. Tegal entered into an employment agreement with Mr. Karis that will become effective at the closing, and Mr. Karis will also be appointed to Tegal’s Board of Directors. Tegal will continue to operate under its current name and ticker symbol for the time being, but plans to seek stockholder approval at its upcoming annual meeting in September 2012 for an amendment to its Certificate of Incorporation, changing its corporate name to CollabRx, Inc.
Originally founded in 2008 by Silicon Valley Internet pioneer Jay (Marty) Tenenbaum, CollabRx has developed clinical advisory networks, expert systems, proprietary tools and processes, and a pipeline of commercial data products and applications (“apps”) for cancer. CollabRx Therapy Finders™, its first commercial product, provides sophisticated, credible, personalized, and actionable information to physicians and patients for rapidly determining which medical tests, therapies, and clinical trials may be considered in cancer treatment planning with a specific emphasis on the tumor genetic profile.
CollabRx Therapy Finders™ are web-based apps that serve as one type of user interface to access proprietary CollabRx content. CollabRx content is dynamically updated and organized in a knowledgebase that includes information on molecular diagnostics, medical tests, clinical trials, drugs, biologics and other information relevant for cancer treatment planning. Capturing how highly respected practicing physicians use this information in the clinical setting further refines the knowledgebase.
Upon the acquisition’s closing, Tegal will issue an aggregate of 236,433 shares of common stock, representing 14% of Tegal’s total shares outstanding prior to the closing, to former CollabRx stockholders in exchange for 100% of the capital stock of CollabRx, Inc. Tegal and certain former CollabRx stockholders will enter into a Stockholders Agreement providing for, among other things, registration rights, transfer restrictions and voting and standstill agreements. Tegal also will assume $500,000 of existing CollabRx indebtedness through the issuance of 5-year promissory notes in substitution for outstanding notes previously issued by CollabRx. In addition, Tegal will grant a total of 368,417 RSUs and options as “inducement grants” to newly hired management and employees, all subject to four-year vesting and other restrictions.
“Medicine is entering a new era of low cost genome sequencing and the proliferation of personalized treatments based on specific genetic mutations,” said James Karis, CEO of CollabRx. “With the technology platform and expert system leadership position that CollabRx has developed over the past few years, we believe that the new company is in a position to lead the market for accurate, credible and current genomic information in the cancer space. We are excited to be joining the Tegal management team in a well-resourced, publicly-traded entity.”
“This acquisition marks both the successful conclusion of a transition process and the beginning of a new chapter for Tegal Corporation,” said Thomas Mika, Tegal’s Chairman, President and CEO. “We are excited to help drive the rapid growth of this market while we meet a critical and consequential human need. This is a mission Tegal’s board has embraced wholeheartedly. I am very pleased to be working with James Karis as Co-CEO and fellow director, and look forward, along with the entire team at CollabRx and Tegal, to building a dynamic company in a new era of genomic medicine.”
About Tegal
Since its founding in 1972, Tegal Corporation has been dedicated to the development and application of emerging technologies. For 40 years, Tegal’s process and equipment know-how has been incorporated in devices fabricated by some of the world’s leading semiconductor and MEMS companies, including Tegal’s one-time parent, Motorola. Now entering its fifth decade, Tegal has committed its future to emerging technologies in medical devices and health care. Please visit us on the web at www.tegal.com.
About CollabRx
CollabRx is a recognized leader in “cloud-based” expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.
Apophis
15 years ago
Tegal Receives Silicon DRIE Tool Order From Precision Timing Device Manufacturer
Tegal Corporation, (Nasdaq:TGAL) an innovator of specialized production solutions for the fabrication of advanced MEMS, power ICs and optoelectronic devices, today announced it has received an order for a Tegal 200 SE DRIE tool, equipped with the Tegal ProNovaTM ICP source, from a leading manufacturer of precision timing devices. Tegal was awarded the 200 SE DRIE tool order after a thorough competitive evaluation by the customer, who will use the silicon DRIE tool to develop MEMS-based precision timing devices
“Tegal is pleased to have our Tegal 200 SE DRIE Silicon Etch System selected by this important manufacturer of precision timing devices. Our customer, with its long-established reputation for producing high-quality products, chose the Tegal DRIE tool after an extensive competitive evaluation,” said Thomas Mika, President and CEO, Tegal Corporation. “We think this particular order is a strong endorsement of the winning value proposition Tegal brings to the silicon DRIE equipment market. Our customer chose Tegal based on our superior silicon DRIE process performance, superior after-sale equipment and process support, and on our ability to provide pre- and post-sale wafer processing services from both our Petaluma, CA and Annecy, France, DRIE process demonstration laboratories.” MEMS-based timing and frequency control devices are making significant inroads into the high-precision timing markets currently served by products based on quartz crystal oscillators. Important industrial and consumer applications for precision timing devices include Global Positioning System navigation units, smartphones and other wireless communication products, cameras, watches and portable media players. Silicon MEMS timing devices, including those incorporating piezoelectric AlN films, are displacing quartz timing devices as a result of the demonstrated ruggedness of the silicon MEMS timing devices in rough-and-tumble applications, and because of their lower cost. Tegal supplies silicon DRIE tools and AlN PVD tools to the timing market for basic research purposes, for process and product development, and for mass production
The Tegal 200 SE system is high-density plasma etch tool featuring the Tegal ProNovaTM inductively coupled plasma etch reactor and magnetic plasma confinement. The tool can run Tegal’s patented SHARP – Super High Aspect Ratio Process, achieving etched feature aspect ratios of greater than 100:1 in production environments. Together with its high reliability, broad process windows, and high etch rates, the Tegal 200 SE system is a critical enabler for etching silicon (SE) films found in the MEMS, bio-tech, power IC, optoelectronic, and 3D-IC markets. Tegal DRIE tools are presently employed in numerous research and development laboratories throughout the world, engaging in both commercial and academic research programs, and are also found in MEMS foundries and other dedicated commercial high volume manufacturing lines world-wide
Safe Harbor Statement Except for historical information, matters discussed in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements, which are based on assumptions and describe our future plans, strategies and expectations, are generally identifiable by the use of the words "anticipate," "believe," "estimate," "expect," "intend," "project" or similar expressions. These forward-looking statements are subject to risks, uncertainties and assumptions about the Company including, but not limited to industry conditions, economic conditions, acceptance of new technologies and market acceptance of the Company's products and services. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements in this paragraph. For a further discussion of these risks and uncertainties, please refer to the Company's periodic filings with the Securities and Exchange Commission
About Tegal Corporation Tegal is an innovator of specialized production solutions for the fabrication of advanced MEMS, power ICs and optoelectronic devices found in products like smart phones, networking gear, solid-state lighting, and digital imaging. The Company’s plasma etch and deposition tools enable sophisticated manufacturing techniques, such as 3D interconnect structures formed by intricate silicon etch, also known as Deep Reactive Ion Etching (DRIE). Tegal combines proven expertise with practical system strategies to deliver application-specific solutions that are robust and reliable, and deliver exceptional process quality and high yields at a lower overall cost of ownership. Headquartered in Petaluma, California, the company has more than 35 years of expertise and innovation in specialized technologies, over 100 patents, and an installed base of more than 1900 systems worldwide. Please visit us on the web at www.Tegal.com
Apophis
15 years ago
Tegal Receives Repeat Silicon DRIE Tool Order From Japan Home Market Customer
Tegal Corporation, (Nasdaq: TGAL) an innovator of specialized production solutions for the fabrication of advanced MEMS, power ICs and optoelectronic devices, today announced it has received a repeat order for a Tegal 200 SE DRIE tool from a leading Japanese provider of MEMS devices. The Tegal 200 SE DRIE tool will ship in the current quarter, and will be used by the customer to rapidly increase production output of commercial MEMS products.
This repeat DRIE system order for Tegal was secured as a result of the continued successful cooperation between Tegal and Canon Marketing Japan, Tegal’s sales partner in Japan for the Tegal DRIE product line.
“Tegal is pleased to have our Tegal 200 SE DRIE Silicon Etch System selected as a repeat order by this important Japanese customer. DRIE process performance, tool repeatability, and etch uniformity are the key factors considered by our customer for again choosing Tegal,” said Yannick Pilloux, DRIE Product Manager, Tegal Corporation. “The fact that our customer has selected Tegal, after working in MEMS production for many years in the Japanese market, is a strong endorsement of the Tegal 200SE’s track record for production performance. I’m convinced that our etch tool will provide the necessary capabilities to further support our customer’s current and future manufacturing requirements.”
The Tegal 200 SE system is high-density plasma etch tool featuring an inductively coupled plasma etch reactor and magnetic plasma confinement. The tool can run Tegal’s patented SHARP – Super High Aspect Ratio Process, achieving etched feature aspect ratios of greater than 100:1 in production environments. Together with its high reliability, broad process windows, and high etch rates, the Tegal 200 SE system is a critical enabler for etching silicon (SE) films found in the MEMS, bio-tech, power IC, optoelectronic, and 3D-IC markets. Tegal DRIE tools are presently employed in numerous research and development laboratories throughout the world, engaging in both commercial and academic research programs, and are also found in MEMS foundries and other dedicated commercial High Volume Manufacturing lines world-wide.
Apophis
15 years ago
Tegal Receives Silicon DRIE Tool Order From Advanced Systems and Technologies Provider
Tegal Corporation, (Nasdaq:TGAL) an innovator of specialized production solutions for the fabrication of advanced MEMS, power ICs and optoelectronic devices, today announced it has received an order for a Tegal 110 S/DE DRIE tool from a leading provider of advanced systems and technologies products. The Tegal 110 S/DE DRIE tool will ship in the current quarter, and will be used by the customer for multiple silicon DRIE and dielectric film DRIE applications.
The DRIE tool order from this first-time Tegal DRIE customer was secured by Tegal following a thorough, multi-vendor competitive evaluation by the customer, which included an inspection visit to Tegal’s Petaluma, CA, DRIE process demonstration laboratory. The Tegal 110 S/DE, with its superior DRIE process results, wide-ranging DRIE process flexibility, robust and user-friendly industrial design, combined with Tegal’s long-standing reputation for award-winning post-sales customer support, represented the best overall value of all the DRIE tools evaluated by the customer, resulting in the present order.
The Tegal 110 S/DE system is a high-density plasma etch tool featuring an inductively coupled plasma etch reactor and magnetic plasma confinement. The tool can run Tegal’s patented SHARP – Super High Aspect Ratio Process, achieving etched feature aspect ratios of >100:1 in production environments. Together with its high reliability, broad process windows, and high etch rates, the Tegal 110 S/DE system is a critical enabler for etching silicon (S) and dielectric (DE) films found in the MEMS/MOEMS, bio-tech, and hi-voltage markets. Tegal DRIE tools are presently employed in numerous research and development laboratories throughout the world, engaging in both commercial and academic research programs, and are also found in MEMS foundries and other dedicated commercial High Volume Manufacturing lines world-wide.
MLD38
19 years ago
Several came from Mattson Tech
...Not sure about those who may have been with Brad Mattson back in the Novellus Systems days...
Mattson : Mr. Edward Chan to the position of President, Tegal Asia-Pacific, and Mr. Birger Gneuss to the position of Vice President & General Manager, Tegal Europe. ---
http://www.tegal.com/pressdetail.aspx?pressReleaseID=17
....Mr. Chan comes to Tegal with over 20 Years of international sales and operations experience with companies such as Mattson Technology and Applied Materials. He has held multiple executive positions in Asian and US corporations and has led or coached start-ups and mid-size companies in China , Taiwan , Singapore , Malaysia and other countries in Asia/Pacific. Mr. Gneuss has more than 20 years of executive sales and management experience in European semiconductor equipment operations with companies such as Lam Research, Mattson Technologies and Tegal Corporation. Both Mr. Chan and Mr. Gneuss have outstanding backgrounds and proven track records of establishing sales and marketing strategies, and achieving industry leading sales results....
Steve Selbrede : Mattson Technology
http://72.14.203.104/search?q=cache:YCbqX1TVOaEJ:www.tegal.com/news_events/nr/nr 040603.html+%22Steve+Selbrede%22&hl=en&lr=&strip=1
June 2004: ...Selbrede is a 27-year veteran of the semiconductor industry, previously holding senior Research & Development management positions with Mattson Technology, Watkins Johnson, Genus, Samsung and National Semiconductor. Most recently, Mr. Selbrede was responsible for the development of the Mattson ICP Strip and Aspen III PECVD tools....
Sept. 13, 2005: Ralph Martin, Former President of Mattson Technology, appointed as Board Member
http://www10.nanotechcafe.com/nbc/articles/view_article.php?section=CorpNews&art icleid=205917
...Ralph Martin was appointed to fill a vacancy as an independent director. Mr. Martin is a 25-year veteran of the semiconductor capital equipment industry who has been an independent industry consultant since 2001. Previously, Mr. Martin served as President of Mattson Technology, a position he held from December 1996 through January 1999. Prior to that he held other senior management positions in Mattson Technology, including Executive Vice President and Chief Operating Officer and Vice President of Engineering. Mr. Martin was also a member of the startup team at Novellus Systems, a company founded by Brad Mattson, Tegal's recently appointed Chairman. Prior to his tenure at Novellus, Mr. Martin held various technical position with GCA, LFE Corp. and MIT Center for Material Science and Engineering....
AV8R
21 years ago
Press Release Source: H-Quotient, Inc.
Business Week Lists H-Quotient in Lahiji's Top Five Holdings
Tuesday March 2, 8:56 am ET
VIENNA, Va.--(BUSINESS WIRE)--March 2, 2004--Business Week listed H-Quotient, Inc. (OTC Bulletin Board:HQNT - News) among the top five holdings of Chris Lahiji, manager of the Lahiji Fund and a portfolio manager of Frontier Equity Fund. The article appears in the March 6, 2004 issue of Business Week.
Lahiji's Top Holdings included Tegal (TGAL), Dynatronics (DTNT), Industries International (IDUL), H-Quotient (HQNT), and Eye Dynamics (EYDY).
President and CEO Douglas Cohn said, "We are gratified to receive such significant recognition. It is a tribute to all of the people who have worked so hard to bring the Company to this point."
This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.
For more information visit the H-Quotient web site at www.hquotient.com
Level up your trading with our powerful tools and real-time insights all in one place.
Penny Roger$
13 years ago
Hot Features
Premium
